icotec established a strategic partnership with MVM Partners, a global healthcare venture capital firm. icotec is commercializing BlackArmor Carbon/PEEK products that may offer significant clinical advantages over traditional metal implants in spine oncology.
Since receiving FDA clearance in 2019, many designated U.S. cancer centers have adopted icotec’s BlackArmor products. This investment will enable icotec to continue development to expand the portfolio into underserved indications of spinal infection and osteoporosis.
icotec established a strategic partnership with MVM Partners, a global healthcare venture capital firm. icotec is commercializing BlackArmor Carbon/PEEK products that may offer significant clinical advantages over traditional metal implants in spine oncology.
icotec established a strategic partnership with MVM Partners, a global healthcare venture capital firm. icotec is commercializing BlackArmor Carbon/PEEK products that may offer significant clinical advantages over traditional metal implants in spine oncology.
Since receiving FDA clearance in 2019, many designated U.S. cancer centers have adopted icotec’s BlackArmor products. This investment will enable icotec to continue development to expand the portfolio into underserved indications of spinal infection and osteoporosis.
Copy to clipboard 
